Immunoquantitation of carnitine palmitoyl transferase in skeletal muscle of 31 patients

Georgirene D. Vladutiu; Isora Saponara; Jeffrey M. Conroy; Robert E. Grier; Linda Brady; Paul Brady

doi:10.1016/0960-8966(92)90057-D

Immunoquantitation of carnitine palmitoyl transferase in skeletal muscle of 31 patients

Georgirene D. Vladutiu, Isora Saponara, Jeffrey M. Conroy, Robert E. Grier, Linda Brady, Paul Brady

Food Science and Nutrition

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

We studied 31 patients suspected of having muscle carnitine palmitoyl transferase 2 (CPT₂) deficiency. The catalytic activity of CPT₂ was measured in muscle biopsies by the isotope exchange method and CPT₂ immunoreactivity was quantitated by an enzyme-linked immunosorbent assay. Nine patients had normal enzyme activity and immunoreactivity. Eight patients had significant deficiencies in catalytic activity (> 3 S.D. below reference mean) of which six were also deficient in immunoreactivity. An additional nine patients were significantly deficient in immunoreactivity with normal catalytic activity and five patients had partial deficiencies in both. At least two categories of alterations in CPT may exist which lead to a deficiency based on the data presented: (1) a regulatory defect in CPT which only alters the enzyme active site; and (2) a structural defect due to altered synthesis, increased degradation, or changes in the immunoreactive site. It may prove to be of diagnostic importance to combine the analysis of enzyme activity and immunoreactivity in patients suspected of having a CPT deficiency and to further investigate the condition of partial CPT deficiency.

Original language	English (US)
Pages (from-to)	249-259
Number of pages	11
Journal	Neuromuscular Disorders
Volume	2
Issue number	4
DOIs	https://doi.org/10.1016/0960-8966(92)90057-D
State	Published - 1992

Bibliographical note

Funding Information:
Acknowledgements--We thank the many physicians who provided tissue from their patients for this study and Drs Linda Duffy, Richard Evans, Edward Fine and Mario Rattazzi for helpful discussion of the data and manuscript. We are also grateful to Drs James Nolan, Mark Ballow and Marie Talty for the loan of their ELISA platereaders and to Dr R. Ronchetti for his support in the early phase of this work. This work was supported in part by a grant from the Women's and Children's Research Foundation of the Children's Hospital of Buffalo. We thank Ms Patricia Jones for typing the manuscript.

Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.

Keywords

Carnitine palmitoyl transferase
enzyme-linked immunosorbent assay
mitochondrial myopathy
muscle disease

Access

10.1016/0960-8966(92)90057-D

OpenUrl availability

Full text

Cite this

@article{ce74fe9a352c4bc18314719f2aa1d708,

title = "Immunoquantitation of carnitine palmitoyl transferase in skeletal muscle of 31 patients",

abstract = "We studied 31 patients suspected of having muscle carnitine palmitoyl transferase 2 (CPT2) deficiency. The catalytic activity of CPT2 was measured in muscle biopsies by the isotope exchange method and CPT2 immunoreactivity was quantitated by an enzyme-linked immunosorbent assay. Nine patients had normal enzyme activity and immunoreactivity. Eight patients had significant deficiencies in catalytic activity (> 3 S.D. below reference mean) of which six were also deficient in immunoreactivity. An additional nine patients were significantly deficient in immunoreactivity with normal catalytic activity and five patients had partial deficiencies in both. At least two categories of alterations in CPT may exist which lead to a deficiency based on the data presented: (1) a regulatory defect in CPT which only alters the enzyme active site; and (2) a structural defect due to altered synthesis, increased degradation, or changes in the immunoreactive site. It may prove to be of diagnostic importance to combine the analysis of enzyme activity and immunoreactivity in patients suspected of having a CPT deficiency and to further investigate the condition of partial CPT deficiency.",

keywords = "Carnitine palmitoyl transferase, enzyme-linked immunosorbent assay, mitochondrial myopathy, muscle disease",

author = "Vladutiu, {Georgirene D.} and Isora Saponara and Conroy, {Jeffrey M.} and Grier, {Robert E.} and Linda Brady and Paul Brady",

note = "Funding Information: Acknowledgements--We thank the many physicians who provided tissue from their patients for this study and Drs Linda Duffy, Richard Evans, Edward Fine and Mario Rattazzi for helpful discussion of the data and manuscript. We are also grateful to Drs James Nolan, Mark Ballow and Marie Talty for the loan of their ELISA platereaders and to Dr R. Ronchetti for his support in the early phase of this work. This work was supported in part by a grant from the Women's and Children's Research Foundation of the Children's Hospital of Buffalo. We thank Ms Patricia Jones for typing the manuscript. Copyright: Copyright 2014 Elsevier B.V., All rights reserved.",

year = "1992",

doi = "10.1016/0960-8966(92)90057-D",

language = "English (US)",

volume = "2",

pages = "249--259",

journal = "Neuromuscular Disorders",

issn = "0960-8966",

publisher = "Elsevier Limited",

number = "4",

}

TY - JOUR

T1 - Immunoquantitation of carnitine palmitoyl transferase in skeletal muscle of 31 patients

AU - Vladutiu, Georgirene D.

AU - Saponara, Isora

AU - Conroy, Jeffrey M.

AU - Grier, Robert E.

AU - Brady, Linda

AU - Brady, Paul

N1 - Funding Information: Acknowledgements--We thank the many physicians who provided tissue from their patients for this study and Drs Linda Duffy, Richard Evans, Edward Fine and Mario Rattazzi for helpful discussion of the data and manuscript. We are also grateful to Drs James Nolan, Mark Ballow and Marie Talty for the loan of their ELISA platereaders and to Dr R. Ronchetti for his support in the early phase of this work. This work was supported in part by a grant from the Women's and Children's Research Foundation of the Children's Hospital of Buffalo. We thank Ms Patricia Jones for typing the manuscript. Copyright: Copyright 2014 Elsevier B.V., All rights reserved.

PY - 1992

Y1 - 1992

N2 - We studied 31 patients suspected of having muscle carnitine palmitoyl transferase 2 (CPT2) deficiency. The catalytic activity of CPT2 was measured in muscle biopsies by the isotope exchange method and CPT2 immunoreactivity was quantitated by an enzyme-linked immunosorbent assay. Nine patients had normal enzyme activity and immunoreactivity. Eight patients had significant deficiencies in catalytic activity (> 3 S.D. below reference mean) of which six were also deficient in immunoreactivity. An additional nine patients were significantly deficient in immunoreactivity with normal catalytic activity and five patients had partial deficiencies in both. At least two categories of alterations in CPT may exist which lead to a deficiency based on the data presented: (1) a regulatory defect in CPT which only alters the enzyme active site; and (2) a structural defect due to altered synthesis, increased degradation, or changes in the immunoreactive site. It may prove to be of diagnostic importance to combine the analysis of enzyme activity and immunoreactivity in patients suspected of having a CPT deficiency and to further investigate the condition of partial CPT deficiency.

AB - We studied 31 patients suspected of having muscle carnitine palmitoyl transferase 2 (CPT2) deficiency. The catalytic activity of CPT2 was measured in muscle biopsies by the isotope exchange method and CPT2 immunoreactivity was quantitated by an enzyme-linked immunosorbent assay. Nine patients had normal enzyme activity and immunoreactivity. Eight patients had significant deficiencies in catalytic activity (> 3 S.D. below reference mean) of which six were also deficient in immunoreactivity. An additional nine patients were significantly deficient in immunoreactivity with normal catalytic activity and five patients had partial deficiencies in both. At least two categories of alterations in CPT may exist which lead to a deficiency based on the data presented: (1) a regulatory defect in CPT which only alters the enzyme active site; and (2) a structural defect due to altered synthesis, increased degradation, or changes in the immunoreactive site. It may prove to be of diagnostic importance to combine the analysis of enzyme activity and immunoreactivity in patients suspected of having a CPT deficiency and to further investigate the condition of partial CPT deficiency.

KW - Carnitine palmitoyl transferase

KW - enzyme-linked immunosorbent assay

KW - mitochondrial myopathy

KW - muscle disease

UR - http://www.scopus.com/inward/record.url?scp=0027089914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027089914&partnerID=8YFLogxK

U2 - 10.1016/0960-8966(92)90057-D

DO - 10.1016/0960-8966(92)90057-D

M3 - Article

C2 - 1483051

AN - SCOPUS:0027089914

SN - 0960-8966

VL - 2

SP - 249

EP - 259

JO - Neuromuscular Disorders

JF - Neuromuscular Disorders

IS - 4

ER -

Immunoquantitation of carnitine palmitoyl transferase in skeletal muscle of 31 patients

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this